AbCellera Biologics (ABCL) Accumulated Depreciation & Amortization: 2020-2025
Historic Accumulated Depreciation & Amortization for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $5.2 million.
- AbCellera Biologics' Accumulated Depreciation & Amortization fell 85.79% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.8 million, marking a year-over-year decrease of 48.79%. This contributed to the annual value of $39.7 million for FY2024, which is 62.81% up from last year.
- Per AbCellera Biologics' latest filing, its Accumulated Depreciation & Amortization stood at $5.2 million for Q3 2025, which was down 4.08% from $5.5 million recorded in Q2 2025.
- AbCellera Biologics' Accumulated Depreciation & Amortization's 5-year high stood at $39.7 million during Q4 2024, with a 5-year trough of $4.8 million in Q1 2024.
- For the 3-year period, AbCellera Biologics' Accumulated Depreciation & Amortization averaged around $20.1 million, with its median value being $24.2 million (2023).
- In the last 5 years, AbCellera Biologics' Accumulated Depreciation & Amortization spiked by 88.02% in 2022 and then slumped by 85.79% in 2025.
- Quarterly analysis of 5 years shows AbCellera Biologics' Accumulated Depreciation & Amortization stood at $9.8 million in 2021, then spiked by 88.02% to $18.5 million in 2022, then soared by 65.67% to $30.6 million in 2023, then increased by 29.76% to $39.7 million in 2024, then tumbled by 85.79% to $5.2 million in 2025.
- Its Accumulated Depreciation & Amortization was $5.2 million in Q3 2025, compared to $5.5 million in Q2 2025 and $5.3 million in Q1 2025.